banner USF Home College of Arts & Sciences OASIS myUSF USF A-Z Index

USF Home > College of Arts and Sciences > Cancer Biology Ph.D. Program

Danielle  Yarde Peekenschneider

Danielle Yarde Peekenschneider

Danielle Yarde Peekenschneider

  

Bio

Dr. Danielle Yarde Peekenschneider successfully defended her dissertation on February 24, 2010. Shown from left to right: Committee members Ed Seto, Ph.D., Lori Hazlehurst, Ph.D., Alvaro Monteiro, Ph.D.; Danielle, Dissertation Chair Dr. Maureen Hoatlin, Oregon Health & Science University, Committee member Michael Schell, Ph.D. and Major Professor William Dalton, Ph.D., M.D. Dr. Peekenschneider accepted a position in the lab of Dr. Stephen Russell, M.D., Ph.D. at the Mayo Clinic, Rochester, MN. She then joined the University of Nebraska Medical Center as a Research Coordinator for Surgery-Transplant. Dr. Peekenschneider is now an institutional research specialist at Northeast Community College in Norfolk, Nebraska.

Dr. Yarde's publication record while in the Program:

Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009 Feb 1;69(3):1009-15. Epub 2009 Jan 20.

Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009 Dec 15; 69(24):9367-75.

Dr. Yarde's publication record since graduation:

Yarde DN, Naik S, Nace RA, Peng KW, Federspiel MJ, Russell SJ. Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV. Cancer Gene Ther. 2013 Nov;20(11):616-21. PMID: 24176894

Yarde DN, Nace RA, Russell SJ. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. Exp Hematol. 2013 Dec;41(12):1038-49. PMID: 24067362

Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol. 2012 Mar 26. doi: 10.1111/j.1365-2141.2012.09099.x.

Monitoring a nuclear factor-kB signature of drug resistance in multiple myeloma.Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM. Mol Cell Proteomics. 2011 Nov;10(11):M110.005520